In vitro susceptibility to gemifloxacin and trovafloxacin of Streptococcus pneumoniae strains exhibiting decreased susceptibility to ciprofloxacin

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 19, Issue 2, 2000, Pages 137-139

  Fuentes, F ^a   Gimenez M J ^b   Marco, F ^c   Alou, L ^a   Aguilar, L ^b   Prieto, J ^a  

^a SCHOOL OF MEDICINE   (Spain)

^b GLAXOSMITHKLINE   (United Kingdom)

^c HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TROVAFLOXACIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; HUMAN; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; SPAIN; STREPTOCOCCUS PNEUMONIAE;

EID: 0034054585     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/s100960050446     Document Type: Article

References (9)

1. 1. Fenoll A, Burgon CM, Muñoz R, Vicioso D, Casai J: Serotype distribution and antimicrobial resistance of Streptococcus pneumoniae isolates causing systemic infections in Spain, 1979-1989. Reviews of Infectious Diseases (1991) 13:56-60
2. 2. Baquero F, García-Rodríguez JA, García de Lomas J, Aguilar L, and the Spanish Surveillance Group for Respiratory Pathogens: Antimicrobial resistance of 1,113 Streptococcus pneumoniae isolates from patients with respiratory tract infections in Spain: results of a 1-year (1996-1997) multicenter surveillance study. Antimicrobial Agents and Chemotherapy (1999) 43:357-359
3. 3. Liñares J, Pallarés R, Alonso T, Pérez JL, Ayats J, Gudiol F, Viladrich PF, Martin R: Trends in antimicrobial resistance of clinical isolates of Streptococcus pneumoniae in Bellvitge Hospital, Barcelona, Spain (1979-1990). Clinical Infectious Diseases (1992) 15:99-105
4. 4. Interpretation of in-vitro sensitivity tests: breakpoints. A guide to sensibility testing. Report of the Working Party on Antibiotic Sensitivity Testing of the British Society for Antimicrobial Chemotherapy. Journal of Antimicrobial Chemotherapy (1991) 27:1-10
5. 5. National Committee for Clinical Laboratory Standards: Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A4. NCCLS, Wayne, PA (1997)
6. 6. Jevons GM, Andrews JM, Wise R: The tentative BSAC break-point of gemifloxacin, a novel fluoroquinolone. Journal of Antimicrobial Chemotherapy (1999) 44, Supplement A:141
7. 7. Pérez-Trallero E, García-Arenzana JM, Jiménez JA, Peris A: Therapeutical failure and selection of resistance to quinolones in a case of pneumococcal pneumonia treated with ciprofloxacin. European Journal of Clinical Microbiology & Infectious Diseases (1990) 9:905-906
8. 8. Körner RJ, Reeves DS, MacGowan AP: Dangers of oral fluoroquinolone treatment in community-acquired upper respiratory tract infections. British Medical Journal (1994) 308:191-192
9. 9. Ewig S, Ruiz M, Torres A, Marco F, Martínez JA, Sánchez M, Mensa J: Pneumonia acquired in the community through drug-resistant Streptococcus pneumoniae. American Journal of Respiratory and Critical Care Medicine (1999) 159:1835-1842